Sanofi, Regeneron to restructure antibody collaboration for Kevzara, Praluent

Under the proposed restructuring, Sanofi is expected to gain sole global rights to Kevzara and sole ex-U.S. rights to Praluent. Regeneron is expected to gain sole U.S. rights to Praluent.

New Delhi: Sanofi and Regeneron Pharmaceuticals, Inc. recently announced their intent to simplify their antibody collaboration for Kevzara (sarilumab) and Praluent (alirocumab) by restructuring into a royalty-based agreement.

Under the proposed restructuring, Sanofi is expected to gain sole global rights to Kevzara and sole ex-U.S. rights to Praluent. Regeneron is expected to gain sole U.S. rights to Praluent. Under the proposed terms of the agreement, each party will be solely responsible for funding development and commercialization expenses in their respective territories.

Also Read: Sanofi, Regeneron gets USFDA approval for cholesterol drug Praluent

These changes are expected to increase efficiency and streamline operations for the products. The existing collaboration relating to Dupixent (dupilumab) will remain unchanged following the restructuring. Completion of the proposed agreement is expected to be finalized in the first quarter of 2020.

Also Read: USFDA approves use of Regeneron, Sanofi eczema drug Dupixent in adolescents